If it passes in the most populous state, the measure could influence national policymaking. Ohio voters will consider a similar measure in 2017 and more may follow in other states. U.S. senators are looking for ways to alleviate “sticker shock” for patients, in light of the uproar over the EpiPen and other dramatic drug price increases.
Many state legislatures considered drug price transparency policies this year and could examine other measures next year. A recent statewide poll on Prop 61, released Nov. 4, showed 47% were both for and against, with 6% undecided or not voting. Previous polling showed a higher rate of supporters and more who were not sure.
